Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Circulation Research. 2004;95:780-788
Published online before print September 23, 2004, doi: 10.1161/01.RES.0000146030.53089.18
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
95/8/780    most recent
01.RES.0000146030.53089.18v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yeh, M.
Right arrow Articles by Berliner, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yeh, M.
Right arrow Articles by Berliner, J. A.
Related Collections
Right arrow Lipid and lipoprotein metabolism
Right arrow Oxidant stress
Right arrow Mechanism of atherosclerosis/growth factors
(Circulation Research. 2004;95:780.)
© 2004 American Heart Association, Inc.

Molecular Medicine

Role for Sterol Regulatory Element-Binding Protein in Activation of Endothelial Cells by Phospholipid Oxidation Products

Michael Yeh, Amy L. Cole, Jenny Choi, Yi Liu, Dmitry Tulchinsky, Jian-Hua Qiao, Michael C. Fishbein, Alek N. Dooley, Talin Hovnanian, Kevin Mouilleseaux, Devendra K. Vora, Wen-Pin Yang, Peter Gargalovic, Todd Kirchgessner, John Y.-J. Shyy, Judith A. Berliner

From the Departments of Medicine (M.Y., A.L.C., J.C., A.N.D., D.K.V., P.G., J.A.B.) and Pathology (M.Y., A.L.C., D.T., J.-H.Q., M.C.F., T.H., K.M., J.A.B.), David Geffen School of Medicine at University of California Los Angeles; Bristol-Myers Squibb, Pharmaceutical Research Institute (W.-P.Y., T.K.), Princeton, NJ; Division of Biomedical Sciences (Y.L., J.Y.-J.S.), University of California, Riverside.

Correspondence to Judith A. Berliner, 13-229 CHS, 650 Charles Young South, Los Angeles, CA 90095-1732. E-mail jberliner{at}mednet.ucla.edu


*    Abstract
up arrowTop
 *Abstract
down arrowIntroduction
 down arrowMaterials and Methods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Oxidized phospholipids, including oxidation products of palmitoyl-arachidonyl-phosphatidyl choline (PAPC), are mediators of inflammation in endothelial cells (ECs) and known to induce several chemokines, including interleukin-8 (IL-8). In this study, we show that oxidized PAPC (OxPAPC), which accumulates in atherosclerotic lesions, paradoxically depletes endothelial cholesterol, causing caveolin-1 internalization from the plasma membrane to the endoplasmic reticulum and Golgi, and activates sterol regulatory element-binding protein (SREBP). Cholesterol loading reversed these effects. SREBP activation resulted in increased transcription of the low-density lipoprotein receptor, a target gene of SREBP. We also provide evidence that cholesterol depletion and SREBP activation are signals for OxPAPC induction of IL-8. Cholesterol depletion by methyl-ß-cyclodextrin induced IL-8 synthesis in a dose-dependent manner. Furthermore, cholesterol loading of ECs by either the cholesterol–cyclodextrin complex or caveolin-1 overexpression inhibited OxPAPC induction of IL-8. These observations suggest that changes in cholesterol level can modulate IL-8 synthesis in ECs. The OxPAPC induction of IL-8 was mediated through the increased binding of SREBP to the IL-8 promoter region, as revealed by mobility shift assays. Overexpression of either dominant-negative SREBP cleavage-activating protein or 25-hydroxycholesterol significantly suppressed the effect of OxPAPC on IL-8 transcription. A role for SREBP activation in atherosclerosis is suggested by the observation that EC nuclei showed strong SREBP staining in human atherosclerotic lesions. The current studies suggest a novel role for endothelial cholesterol depletion and subsequent SREBP activation in inflammatory processes in which phospholipid oxidation products accumulate.


Key Words: oxidized phospholipids • interleukin-8 • endothelium • caveolae • cholesterol


*    Introduction
up arrowTop
 up arrowAbstract
 *Introduction
down arrowMaterials and Methods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Atherosclerosis is a chronic inflammatory process of vascular cells characterized by the entry of monocytes into the vessel wall at all stages of atherogenesis.1 We previously identified oxidized palmitoyl-arachidonyl-phosphatidyl choline (OxPAPC), the most active component of minimally modified low-density lipoprotein LDL (MM-LDL), as an activator of monocyte–endothelial interactions.2 This oxidized phospholipid not only accumulates in atherosclerotic lesions of mice and rabbits2 but also is increased in apoptotic cells, necrotic cells, and cells exposed to oxidative stress.3,4 The importance of these lipids in atherosclerosis is suggested by the observation that polymorphisms of enzymes that mediate the formation of oxidized lipids (ie, myeloperoxidase and lipoxygenase) and enzymes that degrade these lipids (ie, paraoxanase and platelet activating factor) alter susceptibility to atherosclerosis.2

Our previous studies have demonstrated that OxPAPC at a concentration one tenth of that present in the aorta of cholesterol-fed rabbits ({approx}400 µg/gm tissue or 400 µg/mL of combined active lipids)5 is a strong endothelial activator. Treatment of endothelial cells (ECs) in culture with OxPAPC increases the expression of the monocyte-binding molecule CS-1 fibronectin on the apical cell surface6and synthesis of monocyte chemotactic factors (monocyte chemotactic protein 1 and interleukin-8 [IL-8]).7,8 These effects of OxPAPC were not attributable to toxicity and are reversible on its removal.7 The major identified lipids in OxPAPC responsible for IL-8 induction were 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine (POVPC) and 1-palmitoyl-2-epoxyisoprostane E2-sn-glycero-3-phosphocholine (PEIPC). Both of these phospholipids are increased in MM-LDL compared with native LDL.9

OxPAPC induction of IL-8 in ECs is transcriptionally regulated and sustained for 24 hours,8 independent of classical transcription factors nuclear factor {kappa}B (NF-{kappa}B) or activation protein 1. These findings suggest that OxPAPC induces IL-8 transcription by a previously uncharacterized signaling pathway. Our recent data identified a c-Src/STAT3 pathway, transiently activated by OxPAPC (duration of 2 to 4 hours), that mediates the early induction of IL-8.10 The transience of STAT3 activation by OxPAPC indicated that other transcription factors are responsible for the sustained increase of IL-8 transcription by OxPAPC.

Sterol regulatory element-binding proteins (SREBPs) are a family of 3 transcription factors, SREBP1a, SREBP1c, and SREBP2, that mediate cholesterol metabolism.11 SREBP is activated by SREBP cleavage-activating protein (SCAP; an endoplasmic reticulum [ER] protein) cleavage of the SREBP precursor to the active form, which translocates to the nucleus.12 Oxidized LDL (OxLDL) and OxPAPC, which contains bioactive lipids present in (including POVPC and palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine) and absent from (such as PEIPC) OxLDL,13 have been demonstrated to cause the movement of caveolin-1 from caveolae to internal membrane compartments.14 This redistribution is similar to that of methyl-ß-cyclodextrin (MBCD), an agent shown previously to deplete cells of cholesterol, leading to SREBP activation (although such activation was not examined for OxLDL).15,16 The current study presents evidence that OxPAPC and its component lipids cause cholesterol depletion, activation of SREBP, and transcription of downstream targets such as the LDL receptor (LDLR). We also demonstrate increased expression and activation of endothelial SREBP in human atherosclerosis.


*    Materials and Methods
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 *Materials and Methods
down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Reagents and Antibodies
MBCD, cholesterol (water-soluble cholesterol–cyclodextrin complexes), and 25-hydroxycholesterol (25HC) were purchased from Sigma. PAPC was purchased from Avanti Polar Lipids. OxPAPC and POVPC were prepared by procedures described previously.5 PEIPC was isolated from OxPAPC using previous methods.4 Antibodies for Western analyses were from the following sources: caveolin-1 monoclonal (BD Transduction Laboratories), calnexin polyclonal (StressGen Biotechnologies), B-COP mouse ascites fluid (Sigma), paxillin polyclonal, SREBP-1, and SREBP-2 polyclonal, and HRP-conjugated secondary antibodies (Santa Cruz Biotechnology). Western blots were developed by use of enhanced chemiluminescence (ECL) plus reagent (Amersham).

Cell Culture and Treatment
Human aortic ECs (HAECs) were isolated and maintained as described previously.7 Bovine aortic ECs (BAECs) were purchased from VEC Technologies and cultured in DMEM low-glucose media (Irvine Scientific) containing penicillin-streptomycin-glutamine and 15% FBS (Hyclone). Human cell lines (HeLas) were maintained in DMEM high-glucose media containing 10% FBS. HAECs (passages 4 to 8) and BAECs (passages 5 to 17) were used in all experiments. Human microvascular ECs (HMECs) were obtained from the Centers for Disease Control and Prevention and cultured as described previously.17 Cells were treated with OxPAPC (35 to 50 µg/mL) or MBCD (0.05 to 0.3% wt/vol) in media containing 1% FBS. For cholesterol loading, cells were either treated with cholesterol cyclodextrin complex (10 to 20 µg/mL) for 1 hour and then OxPAPC or MBCD was added for 4 hours in the presence of complex, or they were treated with complex, washed 3x, and then treated with OxPAPC or MBCD.

Western Blot Analysis
Procedures for Western blot analysis were as described previously.18 In brief, N-Acetyl-leu-leu-met at a concentration of 200 µmol/L and protease inhibitor cocktail were added to media and PBS (during cell harvest). For Western blotting, samples were separated on 4% to 12% Tris-glycine sodium dodecyl sulfate gels (Gradipore) and developed with ECL plus.

Sucrose Gradient Density Centrifugation
Cells were fractionated by the method of Parton and Hancock19 because it does not use detergent and is therefore more appropriate for lipid extraction and gas chromatography-mass spectrometry (GC-MS) analysis.

Cholesterol Measurements
Cholesterol levels were determined by extracting total lipids from medium (2.0 mL) or equal volumes of pooled cell fractions 1 to 5, which were enriched in caveolin in untreated cells and thus represented the caveolar/lipid raft fraction. Levels of total cholesterol were assessed by enzymatic colorimetric assay or by GC-MS. For analysis by GC-MS, each sample (and cholesterol standard) was spiked with 6 µg d6-(26,26,26,27,27,27)-cholesterol as an internal standard and derivatized with 80 µL of N,O,-bis(trimethylsilyl)trifluoroacetamide containing 1% trimethylchlorosilane (Pierce) and 20 µL of ethyl acetate at 60°C for 2 hours. Cholesterol levels were analyzed using an electron-ionization time-of-flight mass spectrometer (Micromass GCT).

Enzyme-Linked Immunosorbent Assay
IL-8 levels in HAEC supernatants were measured with use of an IL-8 ELISA kit (Quantikine Immunoassay R&D Systems) according to the protocol of the manufacturer.8

Transient Transfection and Promoter Analysis
The pcI-neo expression vector containing the full-length human caveolin-1 cDNA was a gift from Dr E. Smart (University of Kentucky).20 One human IL-8 promoter (1.4 kb) luciferase reporter construct and the NF-{kappa}Bx3–responsive luciferase plasmid were obtained from Dr N. Leitinger (University of Vienna, Austria),8,21 and a second IL-8 promoter reporter construct (1.4 kb) was obtained from Dr K. Matsushima (Tokyo University, Japan).22 The expression plasmids containing active SREBP1, SREBP2, dominant-negative SCAP (ie, SCAP-C), or the human LDLR promoter reporter constructs were as described previously.23 Transient transfection experiments were performed with use of Effectene (Qiagen) or FuGENE-6 (Roche), with protocols provided by manufacturers. Twelve hours after transfection, cells were treated with the agents indicated for 12 hours. Luciferase values were normalized to ß-galactosidase activity or Renilla levels (Promega).

Quantitative Polymerase Chain Reaction
Primer sets used were: LDLR 5'-cgtgcttgtctgtcacctgcaaat-3', 5'-agaactgaggaatgcagcggttga-3'; and GAPDH 5'-cattgccctcaacgaccactttgt-3', 5'-accaccctgttgctgtagccaaat-3'. Reactions were run in triplicate on a Bio-Rad iCycler with the following thermal protocol: 94° for 5 minutes, then 40 cycles of 94° for 15 seconds, 60° for 30 seconds, and 72° for 30 seconds, ending with a slow ramp from 55° to 95° to generate melt-curve data. Comparative data were generated from sample cycle threshold values using the Pfaffl method. All primer sets showed single melt peaks and had correlations >0.99 and polymerase chain reaction (PCR) efficiencies >90%.

Electrophoretic Mobility Shift Assays
Treated cells were washed with cold PBS and lysed in the buffer containing 10 mmol/L HEPES, pH 7.9, 10 mmol/L KCl, 1.5 mmol/L MgCl2, 0.1% Nonidet P-40 (NP-40), 0.5 mmol/L dithiothreitol (DTT), and protease inhibitors. Lysates were centrifuged at 10 000g for 10 minutes. Pellets were resuspended in buffer containing 20 mmol/L HEPES, pH 7.9, 20% glycerol, 420 mmol/L NaCl, 1.5 mmol/L MgCl2, 0.2 mmol/L EDTA, 0.5 mmol/L DTT, 0.1% NP-40, 0.5 mmol/L phenylmethylsulfonyl fluoride, and protease inhibitors. Lysates were centrifuged at 10 000g for 10 minutes, and the supernatants were collected. Double-stranded DNA corresponding to nucleotides -140 to -120 of human IL-8 promoter containing the sterol regulatory element (SRE) was end-labeled with 32P. The radiolabeled probe was then incubated with either 5 ng recombinant SREBP-2 mature form (ie, SREBP2(N))24 or 20 µg isolated nuclear extracts for 20 minutes at 25°. The DNA–protein complexes were resolved by 5% nondenaturing acrylamide gel. The DNA–protein interactions were revealed by autoradiography.

Immunohistochemical Analysis
Sections (4-µm thick) of human carotid atherectomy specimens collected from 7 different individuals were deparaffinized and rehydrated. Immunostaining with either SREBP1 or SREBP2 antibodies (Santa Cruz) was as described previously.25


*    Results
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMaterials and Methods
 *Results
down arrowDiscussion
 down arrowReferences
 
OxPAPC and POVPC Cause Caveolin-1 Redistribution and Change the Levels of Cholesterol in the Caveolar/Lipid Raft Fraction
We demonstrated previously that OxPAPC treatment of BAECs caused a redistribution of caveolin-1 from the caveolae/lipid raft fraction to internal membrane fractions.14 To expand these studies, the effect of OxPAPC and POVPC, as well as MCDB, on caveolin-1 distribution and cholesterol levels was examined. We were unable to test the effect of PEIPC on caveolin or cholesterol because of the difficulty of obtaining sufficient PEIPC for testing. Treatment with OxPAPC and POVPC caused caveolin-1 movement from the caveolar/lipid raft fraction to cytoplasmic fractions containing ER and Golgi markers (Figure 1). Such redistribution started as early as 2 hours after treatment with OxPAPC and continued for at least 4 hours (data not shown). The effect of OxPAPC was similar to that for MBCD26 (Figure 1B). Similar results were obtained with HAECs (Figure 1B, bottom 2 lanes).



View larger version (64K):
[in this window]
[in a new window]
  		Figure 1. Caveolae–cholesterol depletion induced by OxPAPC causes caveolin-1 (Cav-1) redistribution to ER and Golgi fractions. A, Distribution of caveolin-1, paxillin (noncaveolar membrane protein; non-Cav), calnexin (ER protein), or ß-COP (Golgi protein) in sucrose gradient fractions from untreated BAECs. B, Exposing BAECs or HAECs to OxPAPC (35 µg/mL), POVPC (10 µg/mL), or MBCD (0.3% wt/vol) for 4 hours caused caveolin-1 movement to the ER/Golgi fractions. The caveolin lane is the same in A and B. Data represent 3 experiments with similar findings.

Because the caveolar/lipid raft fraction has been shown to be highly enriched in cholesterol compared with other cell membranes,15 we examined the effect of OxPAPC and POVPC on cholesterol levels in this fraction. Cells were exposed to medium alone, PAPC (35 µg/mL), OxPAPC (35 µg/mL), or POVPC (10 µg/mL) for these studies. As determined by enzymatic colorimetric assay or GC-MS, cholesterol levels were decreased by 30% to 40% in the caveolar/lipid raft fractions from BAECs treated with either OxPAPC or POVPC (Figure 2A). On the contrary, the level of cholesterol in the conditioned media from cells treated with OxPAPC and POVPC was increased by 50% to 60% compared with that of control medium or PAPC (Figure 2B). Similar results were observed in HAECs (data not shown). The extent of the caveolin shift relative to untreated cells (Figure 1B) differed slightly in different gradients but the percentage of caveolin in fractions 1 to 5 in cells treated with OxPAPC, POVPC, or MBCD differed from control or PAPC in all experiments. Because of this variability, it is difficult to make an exact correlation of the extent of cholesterol depletion (which was less variable) and the caveolin shift.



View larger version (25K):
[in this window]
[in a new window]
  		Figure 2. OxPAPC, POVPC, and MCBD cause cholesterol depletion and IL-8 upregulation in ECs. A, Cholesterol content decreased in the buoyant fractions1–5 from BAECs treated for 4 hours with OxPAPC (35 µg/mL) or POVPC (10 µg/mL) compared with buoyant fractions from untreated cells or cells treated with PAPC (35 µg/mL). B, Increased cholesterol content in medium from the same cells. C, IL-8 protein levels were increased in HAECs treated with OxPAPC (35 µg/mL), POVPC (10 µg/mL), or MBCD (0.3% wt/vol) for 4 hours but not nonoxidized PAPC (Con). D, MBCD (0.05 to 0.3% wt/vol)–increased IL-8 promoter activity in BAECs was dose dependent. In A and B, data were pooled from 3 separate experiments and are presented as mean±SD. In C and D, experiments represent 3 separate studies. Individual experiments were performed in triplicate and data presented as mean±SD.

Cholesterol Depletion Leads to Induction of IL-8
Next, we tested the role of cholesterol depletion in regulating IL-8 synthesis. HAECs were treated with control media, OxPAPC, POVPC, or 0.3% MBCD, and IL-8 levels were determined in the medium. MBCD increased IL-8 protein secretion into the medium to the same extent as OxPAPC and POVPC (Figure 2C). Because OxPAPC-induced IL-8 expression is transcriptionally regulated, we used IL-8 promoter reporter constructs (pIL8-Luc) to determine whether MBCD also regulated IL-8 at the transcriptional level. MBCD, at 0.3%, maximally stimulated luciferase activity (Figure 2D), but similar to OxPAPC, it did not activate NF-{kappa}B (data not shown). These data suggest that endothelial cholesterol depletion, caused by OxPAPC or MBCD, increases IL-8 transcription independent of NF-{kappa}B activation.

To further confirm the role for cholesterol depletion in OxPAPC-induced IL-8 expression, we tested the effect of cholesterol loading. BAECs or HAECs were treated with cholesterol–cyclodextrin complex for 30 minutes before the addition of OxPAPC to medium containing the complex. The cholesterol content of the cells was increased {approx}2-fold by exposure to the complex, and caveolin-1 redistribution and cholesterol depletion were inhibited by exposure to the complex (Figure 3A and 3B). Cholesterol loading also abolished the OxPAPC or POVPC induction of IL-8 (Figure 3C). To be certain that cholesterol loading rather than the formation of OxPAPC–cholesterol complexes or an OxPAPC–cyclodextrin complex was responsible for the observed inhibition, ECs were exposed to cholesterol–cyclodextrin before OxPAPC treatment. Under these conditions, cholesterol was still an effective inhibitor, although slightly less, of OxPAPC- or MBCD-induced IL-8 expression (Figure 3D). In addition, caveolin-1 overexpression, which increases cholesterol content by 2-fold in BAECs,27 strongly inhibited the OxPAPC- and MBCD- but not tumor necrosis factor-{alpha} (TNF-{alpha})–activated IL-8 promoter construct (Figure 3E). These data support our hypothesis that the depletion of caveolae–cholesterol is an important signaling cue for OxPAPC-induced IL-8 expression in ECs.



View larger version (39K):
[in this window]
[in a new window]
  		Figure 3. The effect of OxPAPC on IL-8 induction can be prevented by cholesterol loading. A, OxPAPC-induced cholesterol depletion in buoyant fractions is inhibited by cholesterol loading. HAECs were either untreated or treated for 1 hour with 20 µg/mL cholesterol–cyclodextrin complex (Chol) followed by 4 hours with medium or OxPAPC (35 µg/mL). Cholesterol complex was also present during the 4-hour treatment. Levels of cholesterol in the buoyant fraction were then measured. Cholesterol complex increased levels of cholesterol compared with medium alone (Con). OxPAPC (Ox 35) significantly decreased cholesterol compared with medium alone. This reduction was inhibited by cholesterol complex (Ox35+Chol). B, Cholesterol loading also reversed OxPAPC-induced movement of caveolin-1 in the same cells used in A. C, Preloading HAEC for 2 hours with cholesterol–cyclodextrin inhibited IL-8 induction by OxPAPC and POVPC (OxPAPC+Chol). Conditions were the same as in A. POVPC (10 µg/mL). D, Preloading ECs with cholesterol–cyclodextrin for 2 hours followed by washing the cells and then treating for 4 hours with 35 µg/mL of OxPAPC or MBCD (0.3%) also inhibited IL-8 induction (Chol+OxPAPC). E, In BAECs, overexpression of caveolin-1 but not empty vector reduced pIL8-Luc (0.1 µg/well) activation by OxPAPC (35 µg/mL) or MBCD (0.3%) but not TNF-{alpha}. All figures represent 3 experiments. For A, B, C, and E, data represent triplicate measurements and are given as mean±SD.

OxPAPC Activates SREBP in ECs
Because OxPAPC and MBCD caused the movement of caveolin-1 to the ER/Golgi fraction (Figure 1A and 1B), we tested whether the depletion of caveolar cholesterol by OxPAPC, as was observed previously with MBCD,16 would activate SREBP. OxPAPC treatment caused a decrease in SREBP1 precursors (125 kDa) and a concurrent increase in the mature form of SREBP1 (68 kDa) in HMECs as well as HeLa cells, another OxPAPC-responsive cell type (Figure 4A). SREBP cleavage induced by OxPAPC was observed after 1 hour of treatment and persisted at 8 hours in OxPAPC-treated HAECs (Figure 4B). However, cholesterol loading reversed the OxPAPC-activated SREBP in HeLa cells (Figure 4A) and HAECs and HMECs (data not shown). These results suggest that cholesterol depletion by OxPAPC mediates SREBP activation.



View larger version (31K):
[in this window]
[in a new window]
  		Figure 4. OxPAPC activates SREBP and increases LDLR transcription in ECs. A, Western blot demonstrating activation of SREBP by treating HeLa cells and HMECs with OxPAPC (35 µg/mL) for 2 hours. Activation of SREBP is shown by cleavage of the 125-kDa form to 68 kDa. Activation was inhibited by cholesterol loading as in Figure 3A. B, Time course of SREBP activation by OxPAPC (35 µg/mL) in HAECs. The Western blot demonstrates a decrease in the precursor form of SREBP (125 kDa). GAPDH levels are shown as a loading control. C, The effect of 4-hour treatment with several concentrations of OxPAPC (10 to 50 µg/mL), PEIPC (0.3 µg/mL), and POVPC (10 µg/mL) on LDLR mRNA levels in HAECs determined by quantitative PCR. D, Overexpression of dominant-negative SCAP (SCAP-C) but not empty vector reduced OxPAPC-activated pLDLR-Luc reporter (0.2 µg/well) in HeLa cells. Data in A and B were replicated in 3 experiments. Data in C and D represent 3 separate experiments performed in triplicate. Data are given as mean±SD.

Quantitative PCR analyses showed that OxPAPC caused a dose-dependent increase in mRNA levels of LDLR in HAECs (Figure 4C) and induced a 6-fold increase in the mRNA level of 3-hydroxy-3-methylglutaryl (HMG) coenzyme A (CoA) synthase (OxPAPC 40 µg/mL; data not shown), both known SREBP targets. PEIPC (0.3 µg/mL), the most bioactive lipid in OxPAPC, also strongly increased the level of LDLR mRNA (Figure 4C) and HMG CoA synthase mRNA (data not shown). POVPC, a less potent IL-8 inducer, only weakly increases LDLR mRNA by 2- to 3-fold (Figure 4C). In a transient transfection experiment, OxPAPC also increased LDLR promoter activation (Figure 4D), which was abolished by overexpression of a dominant-negative mutant of SCAP (SCAP-C) that inhibits movement of SREBP precursor to the Golgi.23 These studies demonstrate that cholesterol depletion by OxPAPC is sufficient to activate SREBP in ECs, which in turn increases the expression of SREBP target genes such as LDLR.

OxPAPC Induction of IL-8 Expression Requires SREBP
To determine whether SREBP activation plays a role in OxPAPC-induced IL-8 expression, we tested the effect of two SCAP inhibitors: 25HC, an agent that facilitates cholesterol translocation from plasma membrane to ER,12 and SCAP-C. One-hour pretreatment with 25HC followed by 4-hour cotreatment with OxPAPC and 25HC resulted in a significant inhibition of IL-8 protein synthesis in HAECs (Figure 5A) and IL-8 promoter activation by OxPAPC in HeLa cells (Figure 5B); 25HC did not reduce the IL-8 protein synthesis in response to phorbol myristoyl acetate (PMA) or TNF-{alpha} in HAECs (data not shown). Confirming a role for SREBP in OxPAPC-induced IL-8 expression, SCAP-C was found to significantly inhibit OxPAPC activation of the IL-8 promoter construct by {approx}60% (Figure 5C). In contrast, overexpression of the active form of SREBP1 or SREBP2 increased pIL8 promoter activity in HeLa cells (Figure 5D). To further delineate the role of SREBP2 in IL-8 induction, we performed electrophoretic mobility shift assays (EMSAs) to investigate the binding of SREBP2 to the IL-8 promoter. As shown in Figure 5E, GST-SREBP2(N) fusion protein binds to an oligonucleotide containing a consensus SRE corresponding to sequence -134 to -125 in the IL-8 promoter. Furthermore, nuclear extracts isolated from OxPAPC- or MBCD-treated cells showed increased binding to the SRE compared with those from nontreated controls. Binding was inhibited by unlabeled oligo (SC) but not by a scrambled oligo (NC). GST-SREBP2(N) and nuclear extracts only bind marginally to a second oligonucleotide (-675 to -659) that contains an SRE that differs from the consensus sequence by one base (data not shown).



View larger version (49K):
[in this window]
[in a new window]
  		Figure 5. IL-8 induction by OxPAPC requires SREBP activation. A, In HAECs, 1-hour pretreatment with 25HC (5 µmol/L) reduced IL-8 secretion induced by OxPAPC (40 µg/mL). B, Pretreatment with 25HC (5 µmol/L) also inhibited pIL8-Luc reporter (0.2 µg/well) activation by OxPAPC in HeLa cells. C, Overexpression of dominant-negative SCAP (SCAP-C 0.3 µg/well) but not empty vector (0.3 µg/well) reduced OxPAPC activation of pIL8-Luc reporter. D, Overexpression of the active form of SREBP-1 and SREBP-2 (the N-termini of SREBP1c and SREBP2) but not the empty vectors in HeLa cells increased pIL8-Luc reporter activation. Cells were collected 24 hours after transfection. Data in A through D represent 3 separate experiments. Each experiment was performed in triplicate, and data represent mean±SD. E, The 32P-labeled oligonucleotides containing a consensus SRE from the IL-8 promoter was incubated with GST-SREBP2(N) fusion protein (5 ng; left) or nuclear extracts (20 µg) isolated from untreated HAECs, cells treated with OxPAPC (35 µg/mL), or cells treated with MBCD (0.3% wt/vol) for 4 hours (right). The DNA–protein complexes were then subjected to EMSA. SC and NC denote the competition by a 50-fold excess of the nonlabeled specific or nonspecific probes, respectively. These data are representative of 2 experiments.

SREBP Activation in Lumenal ECs in Human Atherosclerotic Lesions
To determine the in vivo relevance of SREBP activation in ECs, we performed immunohistochemistry on human atherosclerotic lesions using antibodies that recognize active and precursor forms of SREBP. Consistent with previous data that phospholipid oxidation products accumulate in macrophage-rich areas of atherosclerotic lesions,2 we found that shoulder areas of these lesions, with large numbers of inflammatory cells, showed an overall increase in staining of SREBP-1 and SREBP-2 in nuclear and cytoplasmic regions of the lumenal endothelium (Figure 6A through 6D). Very little staining was observed in the lumenal endothelium of the fibrous cap region, which lacks inflammatory cells (data not shown). Nuclear staining, seen at a higher magnification in Figure 6D, indicates the presence of the activated form of SREBP. We also observed that SREBP nuclear staining was present in the ECs of some but not all vaso vasorum in the inflammatory regions of these atherosclerotic lesions (Figure 6E and 6F); this suggests that endothelial SREBP activation may also be involved in neovascularization. A few macrophages lacking foamy cytoplasm also showed SREBP1 and SREBP2 in the nucleus, which suggests SREBP activation (Figure 6A and 6B). Overall, these studies demonstrate SREBP activation as an important feature of vascular wall cells in atherosclerotic lesions.



View larger version (166K):
[in this window]
[in a new window]
  		Figure 6. Immunohistochemical analyses of human carotid atherectomy samples showing the shoulder region of the lesion. Paraffin-embedded human carotid atherectomy specimens were stained with irrelevant IgG (A), SREBP1-specific antibody (B), and SREBP2-specific antibody (C). D, A higher magnification of an adjacent region to show nuclear staining by SREBP1-specific antibody (arrows). SREBP1-specific (E) and SREBP2-specific (F) antibody staining of the vaso vasorum in the shoulder area of the lesions.


*    Discussion
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMaterials and Methods
 up arrowResults
 *Discussion
down arrowReferences
 
Although most studies have focused on the role of SREBP in hepatic lipogenesis,11,28 several recent studies suggest that under specific stress conditions, SREBP can be activated in ECs.18,23 In this study, we demonstrate that OxPAPC treatment of ECs causes sustained activation of SREBP and induction of SREBP-targeted genes (LDLR and HMG CoA synthase); this activation was also shown to play an important role in IL-8 synthesis. The data in this and in previous studies demonstrate that SREBP activation is mediated by cholesterol depletion of cell membranes. Our studies detected cholesterol depletion in the caveolae/lipid raft fraction, which contains the majority of cell cholesterol. However, because of the continuity of cholesterol transport from the ER to the cell surface,15,29–31 we would expect other cell membranes, including the ER, where SCAP senses cholesterol, to be at least locally depleted of cholesterol.

There are several mechanisms by which OxPAPC might cause cholesterol depletion. (1) It was shown previously that cholesterol can efflux from cells to phospholipid vesicles in serum-free medium and that this efflux is enhanced by the presence of SR-B1,32 which is highly expressed in ECs (data not shown). In the current studies, OxPAPC in either medium containing 2% serum (Figure 2) or in serum-free medium (data not shown) induced cholesterol depletion of caveolae and an increase in cholesterol in the medium. It has been shown that OxPAPC, like the lipids used in previous studies, can form liposomal vesicles.33 The simplest interpretation of the movement of cholesterol from ECs to the medium after OxPAPC treatment is that cholesterol can efflux to OxPAPC or POVPC vesicles as it does to 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine vesicles reported previously. (2) Another possible cause of movement of cholesterol from the ECs to the medium, in the presence of oxidized phospholipids, is the release of small membrane vesicles (that contain cholesterol). A number of laboratories have demonstrated that vesicle formation can occur in the absence of cell death and that vesicle formation is associated with activation of ECs and other cell types.34–36 We have identified several signal transduction pathways by which oxidized phospholipids rapidly activate inflammatory responses in ECs; these include activation of c-Src10 and of adenylate cyclase.37 However, inhibition of these pathways did not prevent SREBP activation (data not shown). Several other pathways activated by OxPAPC may be responsible for vesicle formation.38,39

The involvement of SREBP activation in OxPAPC induction of IL-8 transcription was demonstrated by use of inhibitors of activation (Figure 5) and expression of the active form of SREBP1 and SREBP2 in HeLa cells. We present evidence that SREBP regulates IL-8 transcription by binding to an SRE in the human IL-8 promoter. OxPAPC and MBCD increased the binding of nuclear extracts to a consensus SRE in the IL-8 promoter (Figure 5E), suggesting that SREBP increases IL-8 transcription by promoter activation.

Although hypercholesterolemia has been identified as a risk factor for atherosclerosis, and cholesterol loading of macrophages clearly contributes to atherogenesis, in vivo evidence suggests that ECs in atherosclerotic lesions are depleted of cholesterol. Studies by Kincer et al demonstrated that ECs of apolipoprotein E–null mice fed a high-fat diet have decreased caveolar–cholesterol concentration in the endothelial caveolae.40 This study also suggested that circulating OxLDL causes cholesterol depletion in ECs. Furthermore, high-density lipoprotein, which delivers cholesterol to ECs, reversed the process.41 Consistent with these in vivo findings, our data support the concept that ECs, when challenged with oxidized phospholipids present at the site of chronic inflammation, will respond with caveolar–cholesterol depletion. Our data further show that OxPAPC-induced cholesterol depletion is sufficient to activate SREBP. This mechanism appears to be specific for OxPAPC because other proinflammatory agents, including TNF-{alpha}, lipopolysaccharide, and PMA, were unable to increase activation of SREPB in ECs (data not shown).

The paradoxical activation of SREBP in ECs of atherosclerotic lesions, which are bathed in high levels of lipoproteins, is a surprising finding and could accelerate lesion development by several mechanisms. (1) The induction of IL-8 by SREBP activation could cause monocyte accumulation in lesions. (2) LDLR upregulation could lead to increased LDL transport into the lesions, which would contribute to foam cell formation. (3) Increased levels of LDL processing in ECs would lead to increased oxidative stress,42 and consequent oxidation of lipids by these oxidative pathways would then predispose the arterial wall to a pathologic cycle. In addition to activation of SREBP by oxidized phospholipids, disturbed flow (a known atherogenic stimuli) can prolong SREBP activation in ECs in vitro.23 Oxidation products of phospholipids have been demonstrated to transiently activate ECs by several signal transduction pathways in addition to SREBP.10,37 A combination of these more acutely induced pathways with activation of SREBP is likely responsible for the sustained endothelial activation seen with OxPAPC.

In conclusion, our data demonstrate that OxPAPC depletes cholesterol from specialized compartments in ECs. As a consequence, SREBP is activated, causing sustained induction of IL-8 in vitro. Individual phospholipids such as PEIPC and POVPC (present in OxPAPC) also lead to SREBP activation. We also present evidence for increased endothelial SREBP expression and activation (seen as nuclear localization) in the shoulder regions (enriched in inflammatory cells) of atherosclerotic lesions, where OxPAPC accumulates. These results suggest that cholesterol depletion in ECs is an important signaling pathway in areas of inflammation where oxidized lipids accumulate. Thus, this pathway may represent a novel therapeutic target for atherosclerosis and other diseases of chronic inflammation, such as rheumatoid arthritis, containing abundant oxidized phospholipids. This study and our previous studies suggest that rapid activation of STAT3 and sustained activation of SREBP combine to regulate chemokine synthesis in ECs.


*    Acknowledgments
 
This project was funded by HL07895 (M.Y.), the Giannini Family Foundation (A.L.C.), National Institutes of Health grants HL30568, HL64731 (J.A.B.), HL77448 (J.Y.-J.S.), and K12HD01400 (D.V.), and NSF CHE 0078299 (UCLA Mass Spectrometry Laboratory).


*    Footnotes
 
M.Y. and A.L.C. contributed equally to this work.

Y.L., J.Y.-J.S., and J.A.B. served as cosenior authors.

Original received May 27, 2004; revision received September 10, 2004; accepted September 14, 2004.


*    References
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMaterials and Methods
 up arrowResults
 up arrowDiscussion
 *References
 

  1. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868–874.[CrossRef][Medline] [Order article via Infotrieve]
  2. Berliner J. Introduction. Lipid oxidation products and atherosclerosis. Vascul Pharmacol. 2002; 38: 187–191.[CrossRef][Medline] [Order article via Infotrieve]
  3. Huber J, Vales A, Mitulovic G, Blumer M, Schmid R, Witztum JL, Binder BR, Leitinger N. Oxidized membrane vesicles and blebs from apoptotic cells contain biologically active oxidized phospholipids that induce monocyte-endothelial interactions. Arterioscler Thromb Vasc Biol. 2002; 22: 101–107.[Abstract/Free Full Text]
  4. Subbanagounder G, Wong JW, Lee H, Faull KF, Miller E, Witztum JL, Berliner JA. Epoxyisoprostane and epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis. Formation of these oxidized phospholipids in response to interleukin-1beta. J Biol Chem. 2002; 277: 7271–7281.[Abstract/Free Full Text]
  5. Watson AD, Leitinger N, Navab M, Faull KF, Horkko S, Witztum JL, Palinski W, Schwenke D, Salomon RG, Sha W, Subbanagounder G, Fogelman AM, Berliner JA. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem. 1997; 272: 13597–13607.[Abstract/Free Full Text]
  6. Shih PT, Elices MJ, Fang ZT, Ugarova TP, Strahl D, Territo MC, Frank JS, Kovach NL, Cabanas C, Berliner JA, Vora DK. Minimally modified low-density lipoprotein induces monocyte adhesion to endothelial connecting segment-1 by activating beta1 integrin. J Clin Invest. 1999; 103: 613–625.[Medline] [Order article via Infotrieve]
  7. Lee H, Shi W, Tontonoz P, Wang S, Subbanagounder G, Hedrick CC, Hama S, Borromeo C, Evans RM, Berliner JA, Nagy L. Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res. 2000; 87: 516–521.[Abstract/Free Full Text]
  8. Yeh M, Leitinger N, de Martin R, Onai N, Matsushima K, Vora DK, Berliner JA, Reddy ST. Increased transcription of IL-8 in endothelial cells is differentially regulated by TNF-alpha and oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001; 21: 1585–1591.[Abstract/Free Full Text]
  9. Subbanagounder G, Leitinger N, Schwenke DC, Wong JW, Lee H, Rizza C, Watson AD, Faull KF, Fogelman AM, Berliner JA. Determinants of bioactivity of oxidized phospholipids. Specific oxidized fatty acyl groups at the sn-2 position. Arterioscler Thromb Vasc Biol. 2000; 20: 2248–2254.[Abstract/Free Full Text]
  10. Yeh M. Oxidized phospholipids increase interleukin 8 (IL-8) synthesis by activation of the c-src/signal transducers and activators of transcription, (STAT)3 pathway. J Biol Chem. 2004; 279: 30175–30181.[Abstract/Free Full Text]
  11. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002; 109: 1125–1131.[CrossRef][Medline] [Order article via Infotrieve]
  12. Brown AJ, Sun L, Feramisco JD, Brown MS, Goldstein JL. Cholesterol addition to ER membranes alters conformation of SCAP, the SREBP escort protein that regulates cholesterol metabolism. Mol Cell. 2002; 10: 237–245.[CrossRef][Medline] [Order article via Infotrieve]
  13. Navab M, Fogelman AM, Berliner JA, Territo MC, Demer LL, Frank JS, Watson AD, Edwards PA, Lusis AJ. Pathogenesis of atherosclerosis. Am J Cardiol. 1995; 76: 18C–23C.[CrossRef][Medline] [Order article via Infotrieve]
  14. Walton KA, Cole AL, Yeh M, Subbanagounder G, Krutzik SR, Modlin RL, Lucas RM, Nakai J, Smart EJ, Vora DK, Berliner JA. Specific phospholipid oxidation products inhibit ligand activation of toll-like receptors 4 and 2. Arterioscler Thromb Vasc Biol. 2003; 23: 1197–1203.[Abstract/Free Full Text]
  15. Fielding CJ, Fielding PE. Relationship between cholesterol trafficking and signaling in rafts and caveolae. Biochim Biophys Acta. 2003; 1610: 219–228.[Medline] [Order article via Infotrieve]
  16. Field FJ, Born E, Murthy S, Mathur SN. Regulation of sterol regulatory element-binding proteins by cholesterol flux in CaCo-2 cells. J Lipid Res. 2001; 42: 1687–1698.[Abstract/Free Full Text]
  17. Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC, Lawley TJ. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol. 1992; 99: 683–690.[CrossRef][Medline] [Order article via Infotrieve]
  18. Lin T, Zeng L, Liu Y, DeFea K, Schwartz MA, Chien S, Shyy JY. Rho-ROCK-LIMK-cofilin pathway regulates shear stress activation of sterol regulatory element binding proteins. Circ Res. 2003; 92: 1296–1304.[Abstract/Free Full Text]
  19. Parton RG, Hancock JF. Caveolin and Ras function. Methods Enzymol. 2001; 333: 172–183.[Medline] [Order article via Infotrieve]
  20. Uittenbogaard A, Smart EJ. Palmitoylation of caveolin-1 is required for cholesterol binding, chaperone complex formation, and rapid transport of cholesterol to caveolae. J Biol Chem. 2000; 275: 25595–25599.[Abstract/Free Full Text]
  21. Bochkov VN, Mechtcheriakova D, Lucerna M, Huber J, Malli R, Graier WF, Hofer E, Binder BR, Leitinger N. Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca(++)/NFAT. Blood. 2002; 99: 199–206.[Abstract/Free Full Text]
  22. Mukaida N, Shiroo M, Matsushima K. Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8. J Immunol. 1989; 143: 1366–1371.[Abstract]
  23. Liu Y, Chen BP, Lu M, Zhu Y, Stemerman MB, Chien S, Shyy JY. Shear stress activation of SREBP1 in endothelial cells is mediated by integrins. Arterioscler Thromb Vasc Biol. 2002; 22: 76–81.[Abstract/Free Full Text]
  24. Zeng L, Lu M, Mori K, Luo S, Lee AS, Zhu Y, Shyy JY. ATF6 modulates SREBP2-mediated lipogenesis. EMBO J. 2004; 23: 950–958.[CrossRef][Medline] [Order article via Infotrieve]
  25. Qiao JH, Mertens RB, Fishbein MC, Geller SA. Cartilaginous metaplasia in calcified diabetic peripheral vascular disease: morphologic evidence of enchondral ossification. Hum Pathol. 2003; 34: 402–407.[CrossRef][Medline] [Order article via Infotrieve]
  26. Furuchi T, Anderson RG. Cholesterol depletion of caveolae causes hyperactivation of extracellular signal-related kinase (ERK). J Biol Chem. 1998; 273: 21099–21104.[Abstract/Free Full Text]
  27. Matveev S, van der Westhuyzen DR, Smart EJ. Co-expression of scavenger receptor-BI and caveolin-1 is associated with enhanced selective cholesteryl ester uptake in THP-1 macrophages. J Lipid Res. 1999; 40: 1647–1654.[Abstract/Free Full Text]
  28. Shimano H, Shimomura I, Hammer RE, Herz J, Goldstein JL, Brown MS, Horton JD. Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene. J Clin Invest. 1997; 100: 2115–2124.[Medline] [Order article via Infotrieve]
  29. Fielding CJ, Bist A, Fielding PE. Intracellular cholesterol transport in synchronized human skin fibroblasts. Biochemistry. 1999; 38: 2506–2513.[CrossRef][Medline] [Order article via Infotrieve]
  30. Smart EJ, Ying Y, Donzell WC, Anderson RG. A role for caveolin in transport of cholesterol from endoplasmic reticulum to plasma membrane. J Biol Chem. 1996; 271: 29427–29435.[Abstract/Free Full Text]
  31. Smart EJ, Ying YS, Conrad PA, Anderson RG. Caveolin moves from caveolae to the Golgi apparatus in response to cholesterol oxidation. J Cell Biol. 1994; 127: 1185–1197.[Abstract/Free Full Text]
  32. Yancey PG, Bortnick AE, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, Rothblat GH. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol. 2003; 23: 712–719.[Abstract/Free Full Text]
  33. Salgo MG, Corongiu FP, Sevanian A. Peroxidation and phospholipase A2 hydrolytic susceptibility of liposomes consisting of mixed species of phosphatidylcholine and phosphatidylethanolamine. Biochim Biophys Acta. 1992; 1127: 131–140.[Medline] [Order article via Infotrieve]
  34. Morgan BP, Dankert JR, Esser AF. Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. J Immunol. 1987; 138: 246–253.[Abstract]
  35. Meeusen E. The induction of cytotoxic T-cell responses with H-2 antigens shed from viable lymphocytes. Immunology. 1987; 61: 321–326.[Medline] [Order article via Infotrieve]
  36. Patel KD, Zimmerman GA, Prescott SM, McIntyre TM. Novel leukocyte agonists are released by endothelial cells exposed to peroxide. J Biol Chem. 1992; 267: 15168–15175.[Abstract/Free Full Text]
  37. Cole AL, Subbanagounder G, Mukhopadhyay S, Berliner JA, Vora DK. Oxidized phospholipid-induced endothelial cell/monocyte interaction is mediated by a cAMP-dependent R-Ras/PI3-kinase pathway. Arterioscler Thromb Vasc Biol. 2003; 23: 1384–1390.[Abstract/Free Full Text]
  38. Chatterjee S. Sphingolipids in atherosclerosis and vascular biology. Arterioscler Thromb Vasc Biol. 1998; 18: 1523–1533.[Abstract/Free Full Text]
  39. Birukov KG, Leitinger N, Bochkov VN, Garcia JG. Signal transduction pathways activated in human pulmonary endothelial cells by OxPAPC, a bioactive component of oxidized lipoproteins. Microvasc Res. 2004; 67: 18–28.[CrossRef][Medline] [Order article via Infotrieve]
  40. Kincer JF, Uittenbogaard A, Dressman J, Guerin TM, Febbraio M, Guo L, Smart EJ. Hypercholesterolemia promotes a CD36-dependent and endothelial nitric-oxide synthase-mediated vascular dysfunction. J Biol Chem. 2002; 277: 23525–23533.[Abstract/Free Full Text]
  41. Uittenbogaard A, Shaul PW, Yuhanna IS, Blair A, Smart EJ. High-density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem. 2000; 275: 11278–11283.[Abstract/Free Full Text]
  42. Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L, Subbanagounder G, Faull KF, Reddy ST, Miller NE, Fogelman AM. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res. 2000; 41: 1481–1494.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Lipid Res.Home page
B. J. Van Lenten, A. C. Wagner, C.-L. Jung, P. Ruchala, A. J. Waring, R. I. Lehrer, A. D. Watson, S. Hama, M. Navab, G. M. Anantharamaiah, et al.
Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I
J. Lipid Res., November 1, 2008; 49(11): 2302 - 2311.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
S. Rome, V. Lecomte, E. Meugnier, J. Rieusset, C. Debard, V. Euthine, H. Vidal, and E. Lefai
Microarray analyses of SREBP-1a and SREBP-1c target genes identify new regulatory pathways in muscle
Physiol Genomics, August 14, 2008; 34(3): 327 - 337.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
B. G. Gugiu, K. Mouillesseaux, V. Duong, T. Herzog, A. Hekimian, L. Koroniak, T. M. Vondriska, and A. D. Watson
Protein targets of oxidized phospholipids in endothelial cells
J. Lipid Res., March 1, 2008; 49(3): 510 - 520.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
G. M. Buga, J. S. Frank, G. A. Mottino, A. Hakhamian, A. Narasimha, A. D. Watson, B. Yekta, M. Navab, S. T. Reddy, G. M. Anantharamaiah, et al.
D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet
J. Lipid Res., January 1, 2008; 49(1): 192 - 205.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
A. Kallin, L. E. Johannessen, P. D. Cani, C. Y. Marbehant, A. Essaghir, F. Foufelle, P. Ferre, C.-H. Heldin, N. M. Delzenne, and J.-B. Demoulin
SREBP-1 regulates the expression of heme oxygenase 1 and the phosphatidylinositol-3 kinase regulatory subunit p55{gamma}
J. Lipid Res., July 1, 2007; 48(7): 1628 - 1636.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
Y. S. Chatzizisis, A. U. Coskun, M. Jonas, E. R. Edelman, C. L. Feldman, and P. H. Stone
Role of Endothelial Shear Stress in the Natural History of Coronary Atherosclerosis and Vascular Remodeling: Molecular, Cellular, and Vascular Behavior
J. Am. Coll. Cardiol., June 26, 2007; 49(25): 2379 - 2393.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
N. M. Gharavi, P. S. Gargalovic, I. Chang, J. A. Araujo, M. J. Clark, W. L. Szeto, A. D. Watson, A. J. Lusis, and J. A. Berliner
High-Density Lipoprotein Modulates Oxidized Phospholipid Signaling in Human Endothelial Cells From Proinflammatory to Anti-inflammatory
Arterioscler. Thromb. Vasc. Biol., June 1, 2007; 27(6): 1346 - 1353.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
A. A. Birukova, P. Fu, S. Chatchavalvanich, D. Burdette, O. Oskolkova, V. N. Bochkov, and K. G. Birukov
Polar head groups are important for barrier-protective effects of oxidized phospholipids on pulmonary endothelium
Am J Physiol Lung Cell Mol Physiol, April 1, 2007; 292(4): L924 - L935.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
R. Li, W. Chen, R. Yanes, S. Lee, and J. A. Berliner
OKL38 is an oxidative stress response gene stimulated by oxidized phospholipids
J. Lipid Res., March 1, 2007; 48(3): 709 - 715.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. Zimman, K. P. Mouillesseaux, T. Le, N. M. Gharavi, A. Ryvkin, T. G. Graeber, T. T. Chen, A. D. Watson, and J. A. Berliner
Vascular Endothelial Growth Factor Receptor 2 Plays a Role in the Activation of Aortic Endothelial Cells by Oxidized Phospholipids
Arterioscler. Thromb. Vasc. Biol., February 1, 2007; 27(2): 332 - 338.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M.-L. Liu, M. P. Reilly, P. Casasanto, S. E. McKenzie, and K. J. Williams
Cholesterol Enrichment of Human Monocyte/Macrophages Induces Surface Exposure of Phosphatidylserine and the Release of Biologically-Active Tissue Factor-Positive Microvesicles
Arterioscler. Thromb. Vasc. Biol., February 1, 2007; 27(2): 430 - 435.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
P. S. Gargalovic, N. M. Gharavi, M. J. Clark, J. Pagnon, W.-P. Yang, A. He, A. Truong, T. Baruch-Oren, J. A. Berliner, T. G. Kirchgessner, et al.
The Unfolded Protein Response Is an Important Regulator of Inflammatory Genes in Endothelial Cells
Arterioscler. Thromb. Vasc. Biol., November 1, 2006; 26(11): 2490 - 2496.
[Abstract] [Full Text] [PDF]